A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatmen...
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
"BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto BAT-90
Duración del proyecto: 20 meses
Fecha Inicio: 2024-04-01
Fecha Fin: 2025-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product. The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need. Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation. BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies."